Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this
Recursion uses images of cells and AI to map the biological space and accelerate drug discovery, aiming to reduce the high failure rate of traditional drug development. Its Recursion OS platform supports a pipeline of oncology and rare-disease programs with potential first-in-class or best-in-class therapies, and has demonstrated faster, more efficient IND-enabling progress compared with traditional averages. The company pursues partnerships with pharmaceutical, technology, and data partners to expand the reach and impact of AI-driven drug discovery.
Parse Score
Sources
drugpatentwatch.com shapes more of what AI says about Exscientia than any other source, at 25% of its citations.
exscientia.ai · pmc.ncbi.nlm.nih.gov · sciencedirect.com
Excerpts where Exscientia appeared in the AI's answer
Exscientia and Evotec are recognized for using generative design models
Exscientia : Employs AI to design and optimize molecules, with generative AI-based candidates entering in silico trials, as highlighted in.
Excerpts where Exscientia appeared in the AI's answer
Exscientia : Employs a precision generative design platform ("Centaur Chemist")
Exscientia : Utilizes end-to-end AI design platforms paired with automated target and compound validation loops
Excerpts where Exscientia appeared in the AI's answer
Exscientia (Centaur AI) - Noted for precision-designed translational chemistry.
Excerpts where Exscientia appeared in the AI's answer
Exscientia: Combines AI with automated wet labs to design and evaluate drug candidates
